9:00am - 5:00pm

Our Opening Hours Mon. - Fri.


Call Us For Free Consultation




Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 448

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: % of patients with controled disease (responder and stable patients) at 6 months,  Overall Survival,  Number of participants with treatment-related adverse events as assessed by CTCAE v3.0,

Interventions: Standard Chemotherapy (Pemetrexed and Cisplatin), Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab


Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: January 2015

Completion Date: September 2016

Last  Posted Date: September 2, 2016

Location: Centre Hospitalier du Pays d’Aix, Aix-en-Provence, France

Website Link: https://ClinicalTrials.gov/show/NCT00651456

Was this article helpful?
Dislike 0